Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system and release of pro-inflammatory mediators. Drugs available for psoriasis show some limits as tolerability and route of administration. Apremilast, Otezla, is an oral small molecule recently approved for the treatment of patients with moderate-to-severe plaque psoriasis. Compared to biologics that target a single cytokine, apremilast, degrading phosphodiesterase 4 (PDE4), interferes with cyclic anti-microbial peptides, which is involved in the transduction of intracellular signals, controlling the balance of pro-inflammatory and anti-inflammatory signals. Areas covered: This review reported the latest data available from Phase I, II and III trials on apremilast for the treatment of plaque psoriasis. A focus on the clinical management of apremilast, safety and clinical efficacy based on two pivotal clinical trials (ESTEEM 1 and ESTEEM 2) currently ongoing was described. A systematic search was conducted using the PubMed Medline database for primary articles. Expert opinion: Apremilast treatment was demonstrated effective and well tolerated in Phase II and III clinical trials. Several drug peculiarities, such as the low frequency of adverse events and the oral route of administration, make apremilast an innovative treatment for moderate-to-severe psoriasis.

Chimenti, M.s., Gramiccia, T., Saraceno, R., Bianchi, L., Garofalo, V., Buonomo, O.c., et al. (2015). Apremilast for the treatment of psoriasis. EXPERT OPINION ON PHARMACOTHERAPY, 16(13), 2083-2094 [10.1517/14656566.2015.1076794].

Apremilast for the treatment of psoriasis.

CHIMENTI, MARIA SOLE;GRAMICCIA, TALIA;SARACENO, ROSITA;BIANCHI, LUCA;BUONOMO, ORESTE CLAUDIO;PERRICONE, ROBERTO;CHIMENTI, SERGIO;CHIRICOZZI, ANDREA
2015

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system and release of pro-inflammatory mediators. Drugs available for psoriasis show some limits as tolerability and route of administration. Apremilast, Otezla, is an oral small molecule recently approved for the treatment of patients with moderate-to-severe plaque psoriasis. Compared to biologics that target a single cytokine, apremilast, degrading phosphodiesterase 4 (PDE4), interferes with cyclic anti-microbial peptides, which is involved in the transduction of intracellular signals, controlling the balance of pro-inflammatory and anti-inflammatory signals. Areas covered: This review reported the latest data available from Phase I, II and III trials on apremilast for the treatment of plaque psoriasis. A focus on the clinical management of apremilast, safety and clinical efficacy based on two pivotal clinical trials (ESTEEM 1 and ESTEEM 2) currently ongoing was described. A systematic search was conducted using the PubMed Medline database for primary articles. Expert opinion: Apremilast treatment was demonstrated effective and well tolerated in Phase II and III clinical trials. Several drug peculiarities, such as the low frequency of adverse events and the oral route of administration, make apremilast an innovative treatment for moderate-to-severe psoriasis.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/16 - Reumatologia
Settore MED/35 - Malattie Cutanee e Veneree
English
apremilast, biological therapy, Otezla, phosphodiesterase 4, psoriasis, small molecule
Chimenti, M.s., Gramiccia, T., Saraceno, R., Bianchi, L., Garofalo, V., Buonomo, O.c., et al. (2015). Apremilast for the treatment of psoriasis. EXPERT OPINION ON PHARMACOTHERAPY, 16(13), 2083-2094 [10.1517/14656566.2015.1076794].
Chimenti, Ms; Gramiccia, T; Saraceno, R; Bianchi, L; Garofalo, V; Buonomo, Oc; Perricone, R; Chimenti, S; Chiricozzi, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Apremilast for the treatment of psoriasis.pdf

non disponibili

Descrizione: Articolo principale
Licenza: Copyright dell'editore
Dimensione 288.21 kB
Formato Adobe PDF
288.21 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/119541
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 16
social impact